Results 191 to 200 of about 280,842 (293)

Screening for Social Determinants of Health in Patients With Systemic Lupus Erythematosus: A Point‐of‐Care Feasibility Study

open access: yesArthritis Care &Research, EarlyView.
Objective Social determinants of health (SDoH) can impact outcomes but are not routinely screened for in US outpatient rheumatology clinics. This study determined the feasibility of routine point‐of‐care SDoH screening among patients with systemic lupus erythematosus (SLE) and associated barriers and facilitators at the physician, care team, and ...
S. Sam Lim   +11 more
wiley   +1 more source

Broadly applicable PCR restriction fragment length polymorphism method for genotyping bovine leukemia virus. [PDF]

open access: yesJ Vet Med Sci, 2019
Nishikaku K   +6 more
europepmc   +1 more source

The Potential for Extracellular Vesicles in Nanomedicine: A Review of Recent Advancements and Challenges Ahead

open access: yesAdvanced Biology, EarlyView.
Extracellular vesicles (EVs) play a dual role in diagnostics and therapeutics, offering innovative solutions for treating cancer, cardiovascular, neurodegenerative, and orthopedic diseases. This review highlights EVs’ potential to revolutionize personalized medicine through specific applications in disease detection and treatment.
Farbod Ebrahimi   +4 more
wiley   +1 more source

RhoA and Rac1 as Mechanotransduction Mediators in Colorectal Cancer

open access: yesAdvanced Biology, EarlyView.
Analysing RhoA and Rac1 protein levels in Colorectal cancer (CRC) samples under mechanical strain highlights their potential as diagnostic markers. Monitoring their activity could offer valuable insights into how cancer spreads, paving the way for new approaches to better understand and diagnose colorectal cancer.
Sharda Yadav   +5 more
wiley   +1 more source

Inhibition of Glutamine Metabolism Attenuates Tumor Progression Through Remodeling of the Macrophage Immune Microenvironment

open access: yesAdvanced Biology, EarlyView.
The prodrug strategy used in this study offers new promise for cancer metabolism‐based therapies. JHU083, a prodrug that, when cleaved by protease in the tumor microenvironment, yields the glutamine antagonist DON. JHU083 inhibits tumor growth by targeting glutamine‐addicted cancer cells and suppressing glutamine‐dependent M2 macrophages, leading to a ...
Tianhe Li   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy